Rapid molecular diagnostic testing (RMDT) detects enterococci and vancomycin resistance genes (vanA/B) directly from positive blood cultures, enabling earlier identification and antimicrobial therapy
Target Population
Patients with VRE bacteremia, including immunocompromised patients such as those with hematologic malignancies
Care Setting
Hospital setting with blood culture diagnostics and antimicrobial stewardship programs
Key Highlights
RMDT implementation shortened median time to active antimicrobial therapy from 32 to 21 hours (P < .001)
No significant difference in 30-day mortality between RMDT and non-RMDT groups overall (31.6% vs 36.5%, P = .230)
Subgroup analysis excluding leukemia patients showed decreased 30-day mortality with RMDT (29.6% vs 40.8%, P = .037), but this was not sustained on multivariate analysis
Guideline-Based Recommendations
Diagnosis
Use rapid molecular diagnostic tests to detect Enterococcus species and vanA/B genes directly from positive blood culture broths
Confirm vancomycin resistance by minimum inhibitory concentration ≥32 µg/mL per Clinical and Laboratory Standards Institute guidelines
Management
Initiate active antimicrobial therapy promptly upon identification of VRE to reduce time to effective treatment
Incorporate antimicrobial stewardship programs with prior authorization and postprescription review for VRE-active agents
Develop institutional guidelines for interpretation of RMDT results and antimicrobial therapy
Monitoring & Follow-up
Monitor time from blood culture collection to receipt of active antimicrobial therapy
Track 30-day mortality and clinical outcomes in patients with VRE bacteremia
Review antimicrobial use and stewardship interventions regularly
Risks
Delayed appropriate antimicrobial therapy (>48 hours) is associated with increased 30-day mortality
RMDT may not independently improve mortality outcomes despite faster diagnosis and treatment initiation
Patient & Prescribing Data
Patients with confirmed VRE bacteremia, including immunocompromised individuals
RMDT use leads to earlier administration of active antimicrobials but does not clearly reduce overall mortality; empiric therapy may be influenced by clinical context such as leukemia status
Clinical Best Practices
Implement RMDT for rapid detection of VRE in positive blood cultures to reduce time to active therapy
Maintain robust antimicrobial stewardship programs to guide appropriate use of VRE-active agents
Interpret RMDT results within clinical context and confirm with susceptibility testing
Recognize that faster diagnosis alone may not improve mortality; comprehensive clinical management remains essential
by Michael R Hovan, Michael J Burkitt, Sierra A Derti, Judith U Hargrave, Angela S De Cordova, Matthew S Simon, Stephen G Jenkins, Lars F Westblade, Michael J Satlin
Dr. Eunice Wang reviews what plans and protocols are in place to keep our non-COVID-19 patients safe and continued on their treatment plan, while Dr. Brahm Segal discusses how we are managing therapies for our COVID-19 positive patients.
